See the DrugPatentWatch profile for Jornay
When does the Jornay PM patent expire?
Jornay PM (methylphenidate hydrochloride extended-release, taken at bedtime) is a branded pharmaceutical product. Patent-expiration timing depends on which specific intellectual-property protection is being discussed (for example, the active-ingredient patent versus later formulation/use patents), and on country.
The most reliable way to check the exact patent-expiration dates for Jornay PM is to look up the brand in a patent-focused database such as DrugPatentWatch, which tracks patent and exclusivity timelines by product and geography. Use this search page for Jornay PM: DrugPatentWatch – Jornay PM
Does patent expiry always mean generic Jornay PM can launch immediately?
Usually not. Even after a relevant patent expires, market entry can still be blocked by:
- Other unexpired patents for the same product or related formulations/dosing regimens.
- Regulatory exclusivities that can extend market protection beyond patent life.
- Any ongoing litigation that may delay FDA approval/launch timing.
So the practical “first generic launch” date can be later than the first patent expiry date.
What other exclusivity dates should you check besides patents?
If you’re trying to estimate when competition can enter, check both:
- Patent expiration dates (listed per patent family/claim set).
- Regulatory exclusivity (which can add time even if the core patent expires).
A DrugPatentWatch entry typically provides a consolidated view of these protection layers for the brand: DrugPatentWatch – Jornay PM
Which jurisdiction matters (US, EU, UK, etc.)?
Patent and exclusivity rules differ by jurisdiction. A “Jornay PM patent expiration” answer in the US may not match the UK or EU. DrugPatentWatch is particularly useful when you select the geography relevant to your question via its product listing: DrugPatentWatch – Jornay PM
If you tell me the country, I can narrow it to the exact date
“Patent expiration” for Jornay PM can’t be pinned to a single date without the country (and sometimes without which patent listed). If you share whether you mean US, EU/UK, or another market, I can help you interpret the relevant expiry timeline from the patent listing.
Sources
- DrugPatentWatch – Jornay PM